1. Home
  2. AMSF vs CTMX Comparison

AMSF vs CTMX Comparison

Compare AMSF & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMERISAFE Inc.

AMSF

AMERISAFE Inc.

HOLD

Current Price

$32.50

Market Cap

630.9M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$5.03

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMSF
CTMX
Founded
1985
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
630.9M
596.2M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
AMSF
CTMX
Price
$32.50
$5.03
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$50.33
$11.30
AVG Volume (30 Days)
165.9K
8.2M
Earning Date
04-28-2026
03-16-2026
Dividend Yield
8.05%
N/A
EPS Growth
N/A
N/A
EPS
2.47
N/A
Revenue
$317,252,000.00
$76,201,000.00
Revenue This Year
$8.06
N/A
Revenue Next Year
$6.34
$16.91
P/E Ratio
$13.26
$22.58
Revenue Growth
2.66
N/A
52 Week Low
$32.00
$0.40
52 Week High
$53.27
$8.21

Technical Indicators

Market Signals
Indicator
AMSF
CTMX
Relative Strength Index (RSI) 32.00 48.55
Support Level $32.00 $4.92
Resistance Level $39.25 $6.20
Average True Range (ATR) 0.92 0.61
MACD -0.05 -0.01
Stochastic Oscillator 0.00 16.63

Price Performance

Historical Comparison
AMSF
CTMX

About AMSF AMERISAFE Inc.

AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: